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The objective of this phase II and pharmacologic study was to explore the feasibility, toxicity and activity of adaptive intrapatient dose
escalation of cisplatin in a dose-intensive weekly schedule using predefined levels of exposure, with the ultimate aim to improve the
antitumour activity of the therapy in patients with nonsmall cell lung cancer (NSCLC). Platinum DNA-adduct levels in peripheral
white blood cells during treatment were used as the primary parameter for adaptive dosing. If DNA-adduct levels were not available,
the area under the concentration–time curve (AUC) of unbound platinum in plasma was used for dose adaptation. Target levels for
DNA-adducts and AUC have been defined in a previously performed pharmacologic study. The feasibility of adaptive dosing was
tested in 76 patients with stage IIIB and IV NSCLC, who were planned to receive 6 weekly courses of cisplatin at a starting dose of
70 mg m2, together with daily low oral dose of 50 mg VP16. In total, 37 patients (49%) who were given more than one course
received a dose increase varying from 10 to 55%. The majority of patients reached the defined target levels by a dose increase during
course two. Relevant grade 2 neurotoxicity was observed in eight (10%) patients and reversible ototoxicity grade 2 in 14 (18%)
patients. The strategy of adaptive intrapatient dose adjustment of cisplatin is practically feasible in a research setting even when results
for dose adaptation have to be reported within a short time-period of 1 week. The toxicity appeared to be manageable in this cohort
of patients. In some patients, exposure after the standard dose was substantially lower than the defined target level and significant
dose escalations of more than 50% had to be applied. The response rate (RR) was relatively high: overall 40% (29 out of 72 patients)
partial remission (PR), in patients with stage IIIB the RR was 60% (15 out of 25 patients) and with stage IV 30% (14 out of 47 patients).
Randomised studies are needed to determine whether the adaptive dosing strategy results in better efficacy than standard dosing.
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The prognosis of patients with advanced nonsmall cell lung cancer
(NSCLC) remains poor and this stresses the need to develop novel
treatment strategies. Cisplatin is one of the most frequently applied
agents in the treatment of advanced NSCLC. Treatment with
cisplatin-based chemotherapy has a small but statistically sig-
nificant positive influence on survival (Ruckdeschel, 1990; Souquet
et al, 1995; Non-small Cell Lung Cancer Collaborative Group, 1995;
Van Zandwijk and Giaccone, 1996). Trials comparing supportive
care and supportive care plus cisplatin-based chemotherapy
revealed a 27% reduction in the risk of death and an increased
1-year survival of 10% (Non-small Cell Lung Cancer Collaborative
Group, 1995). Another meta-analysis showed that the response rate
of cisplatin in combination with VP16, or various other anticancer
agents, was 34% in stage IIIB and only 22% in stage IV disease
(Ramanathan et al, 1997). Cisplatin is also one of the most active
agents in the treatment of advanced cervical cancer, mesothelioma,
and head and neck (H/N) cancer. Cisplatin is used in the standard
treatment for metastatic ovarian cancer and testicular cancer
(Loehrer and Einhorn, 1984; Krarup-Hansen and Hanse, 1991;
Kaye et al, 1992; Bajorin et al, 1993). In all these tumour types,
including NSCLC, further improvement of therapy with cisplatin
has been extensively investigated. Cisplatin has been used in
combinations with other different chemotherapeutic agents, such
as DNA-alkylators, topoisomerase II inhibitors, vinorelbine and
gemcitabine (Fukuoka et al, 1992; Liu, 1993; Sculier et al, 1994;
Gridelli et al, 1996; Wozniak et al, 1998; Lippe et al, 1999). Besides
evaluation of different combinations of cisplatin, important other
approaches have focused on increasing the dose and/or the dose
intensity of the drug using higher doses per course (Klastersky
et al, 1986; Gandara et al, 1993), or shortening the treatment
interval (Planting et al, 1993, 1994, 1995a, b, 1996a, b, 1997, 1999).
Cisplatin when applied as a single agent at a 3- or 4-weekly
schedule and a dose of 100 mg m2 has a low activity in advanced
NSCLC and the overall response rate (RR) varies from 12 to 15%
(Gandara et al, 1993; Wozniak et al, 1999). In several tumour types,
a significant relation has been suggested between the dose intensity
of cisplatin and the likelihood of response and response duration
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(Ozols and Young, 1984; Gandara et al, 1989; Kaye et al, 1992). For
NSCLC results have been less clear (Klastersky et al, 1986; Gandara
et al, 1993; Gralla et al, 1998).
The highest dose intensity reached in these studies was
41 mg m2 week1 (Gandara et al, 1993). The dose per course of
cisplatin is limited because of the induction of acute intolerable
side effects, in particular acute gastrointestinal (GI) toxicity,
ototoxicity and renal dysfunction. In most patients, GI toxicity and
renal toxicity can adequately be prevented by use of 5HT3 blockers
in combination with dexamethasone as antiemetics and by
rigorous pre- and posthydration. Inspite of these measures, the
dose per course can reasonably not be pushed significantly higher
than approximately 100 mg m2. Since cisplatin as a single
agent has little myelosuppressive effects when applied at
standard doses a realistic option is to shorten the treatment
interval. This has extensively been explored in several phase
I and II studies. In these studies, cisplatin has been applied
in weekly schedules as a single agent as well as in combination
with VP16 and recently also paclitaxel (Planting et al, 1993,
1994, 1995a, b, 1996a, b, 1997, 1999). In the weekly schedule of
cisplatin, VP16 was added at a daily low oral dose, because the two
drugs appear to act at least additively (Tsai et al, 1989; Wampler
et al, 1992) and maybe even synergistically, which has been
established in preclinical models (Kanzawa et al, 1997). In the
phase II studies, cisplatin treatment was found active when used at
a dose of 70 mg m2 in six courses during 7 weeks (i.e. week 1,2,3
and 5,6,7) in combination with VP16 in advanced cervical cancer,
pleural mesothelioma, melanoma and NSCLC (Planting et al, 1997,
1999).
In a pharmocokinetic– dynamic study in 29 patients who
received weekly cisplatin plus daily low-dose VP16, a significant
correlation was found between the area under the unbound plasma
concentration–time curve (AUC) of cisplatin (measured as
platinum by atomic spectroscopy (AAS)) and the likelihood of
tumour response (Schellens et al, 1996). In addition, a highly
significant difference was found between DNA-adduct levels of
platinum, as measured in peripheral white blood cells (WBC) by
AAS in responders (n¼ 10) and non-responders (n¼ 19). The
adduct level in responders was 55% higher compared with
nonresponders at 1 h after the end of the 3-h infusion of cisplatin.
Also at later time points, the responders had significantly higher
WBC DNA-adduct levels than nonresponders. There was also a
highly significant correlation (Po0.001) and linear relation
between the AUC of cisplatin and the DNA-adduct levels in
WBC indicating that variation in the adduct levels is largely
determined by pharmacokinetic variability of cisplatin. In two
recent studies, the feasibility of intrapatient dose adjustment has
been evaluated (manuscript submitted). This has resulted in the
current study to adapt doses of cisplatin during treatment using as
a target the mean value of the platinum DNA-adduct levels in WBC
and AUC of unbound platinum as observed during course one in
the responding patients of the previous pharmacologic study
(Schellens et al, 1996).
METHODS
Selection of patients
Patients were eligible if they had histologically confirmed stage
IIIB or IV NSCLC, they were older than 18 and younger than 80
years, had a life expectancy of at least 3 months, if they had
measurable disease according to WHO criteria (WHO, 1979), a
WHO performance score of 2 or better, adequate bone marrow
function (WBC 43.0 109 l1, platelets 4100 109 l1), adequate
liver (serum bilirubin o25 mmol l1, serum albumine 25 g l1) and
renal function (serum creatinine o140 mmol l1, or creatinine
clearance 445 ml min1). They were not eligible if they had
received radiotherapy on the indicator lesion, or when any
radiotherapy was given within 4 weeks prior to start of the study.
New measurable metastases in previously irradiated areas were
accepted as indicator lesions. Patients were also ineligible if they
had neurologic disease that could cause an increased risk for
peripheral or central neurotoxicity, if they had uncontrolled
infections, if they were pregnant or were lactating, or if they had
known cerebral or leptomeningeal metastases. Previous treatment
with cisplatin or carboplatin was not allowed. Patients had to give
written informed consent. The study was approved by the local
ethics committee.
Treatment schedule
Cisplatin was administered in six courses during 7 weeks, which
was on days 1, 8, 15, 29, 36 and 43. Low-dose VP16 was given as an
oral daily dose of 50 mg on days 1–15 and 29–43. Cisplatin was
administered in 250 ml of 3% NaCl as a continuous i.v. infusion of
3 h. Patients were prehydrated with 0.75 l dextrose/saline plus
20 mmol KCl and 2 g MgSO4 administered in 3 h prior to the 3-h
infusion of cisplatin. After the end of the cisplatin infusion,
patients received posthydration with 2 l of dextrose/saline plus
40 mmol KCl and 4 g. MgSO4 administered over 14 h.
Blood sampling for pharmacokinetic and platinum
DNA-adduct measurements
During each of the first three courses, blood samples were to be
taken at 0, 1, 2, 3, 3.5, 4, 5, 6 and 21 h after start of the infusion. The
volume of each sample was 4 ml except at time points 0, 4 and 21 h
where a volume of 16 ml was collected. Samples at these three time
points were also used for the collection of WBC and measurement
of platinum DNA-adduct levels, according to a previously
validated quantitative assay (Ma et al, 1995).
During each of the last three courses only three blood samples
were taken of 16 ml at time points 0, 4 and 21 h after start of the
infusion of cisplatin.
Urine collection
During the first three courses 24 h urine was collected in two
portions for measurement of the platinum excretion.
Dose-individualisation
The dose of cisplatin that was to be administered during the
second course depended on the pharmacokinetic measurements of
cisplatin in plasma and the DNA-adducts in WBC. The secondary
target was the AUC of unbound platinum in plasma. The algorithm
for dose adaptation is summarised in Figure 1. The starting dose in
all patients was 70 mg m2 according to the previously performed
phase II study (Planting, 1996). As a basis for dose-individualisa-
tion, the pharmacologic data were used of a large pharmacoki-
netic–pharmacodynamic study in 45 patients who received
cisplatin at a dose of 70 or 80 mg m2 (Schellens et al, 1996). In
that study, the mean AUA (area under the DNA-adduct
concentration–time curve) in the group of responders to cisplatin
therapy was rounded off to 23 (mean 22.6, range 11.5–32.1 (pg
PT h mg1 DNA)). In the nonresponders, the mean AUA was
rounded off to 14 (mean 13.7, range 7.4 – 21.3 (pg Pt h mg1 DNA)).
The AUA value of 23, the mean value observed in the responders,
was taken as the target value for the current dose-individualisation
study.
If, in the current study, the observed AUA during course one
was below this defined target value of 23, the patient received a
subsequent dose increase in order to achieve an AUA value of 23
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during the second course. If the observed AUA during the second
course was found to be below 23 again, then a second dose increase
was applied. The maximum allowable dose increase was set at 30%
per course for safety reasons. If the observed AUA during the first
course was found to be higher than 23, then no dose reduction was
applied, and the patient continued treatment at the starting dose of
70 mg m2 during all courses, since the safety of this dose had
previously been shown.
In the previous pharmacologic study, the mean AUC in the
responders was 3.0 (range 2.30 – 3.82 (mg h ml)1) and the AUC in
nonresponders was 2.2 (range 1.10 – 3.16 (mg h ml)1). If, in the
current study, for any reason the AUA could not be determined
then a target AUC value of 3.0 was used for adaptive dosing.
Hence, if the observed AUC was below 3.0 during course one a
dose increase was applied during course two and if the observed
AUC during course two was still below 3.0 then a second dose
increase was applied with a maximum increase per course of 30%,
exactly according to the approach as outlined for the AUA. If the
observed AUC during course 1 was higher than the defined target
of 3.0, then no dose reduction was applied.
In the previous pharmacologic study also a significant relation
was found between the AUC as well as the AUA and the toxicity, in
particular the thrombocytopenia. The AUC, but not AUA, was also
significantly correlated with the neurotoxicity (in particular, the
log vibration perception threshold). For this reason, a maximum
value of the AUC was accepted, which was arbitrarily set at 3.4 (the
mean value in the responders plus one standard deviation, as
observed in the pharmacologic study). If, for example, a patient
needed a dose increase, because the observed AUA was below the
defined target, but the AUC after the planned dose increase was
expected to exceed the safety limit of 3.4, then no or a lower than
planned dose increase was applied for safety reasons.
The dose and schedule of VP16 were not changed during
the study
After the end of the planned six courses of cisplatin, patients who
showed a tumour response and no unacceptable toxicity would in
principle be treated with 21-day courses of daily oral 50 mg VP16
b.i.d., courses to be repeated on day 28 according to the schedule
of the previously performed phase II study in NSCLC (Planting,
1996). However, continuation of treatment was left to the
discretion of the responsible physician.
Follow-up studies
Prior to start and every week during treatment a physical
examination was performed and the toxicity score (according to
the Common Toxicity Criteria (CTC)) and WHO performance
score were determined. In addition, haematologic parameters
(haemoglobin, leukocyte, granulocyte and platelet counts), serum
chemistry (liver (ASAT, ALAT, gamma-GT, LDH, alkaline,
phosphatase, bilirubin) and renal function (serum creatinine and
measured creatinine clearance), serum albumin and Na, K, Mg, Ca)
were determined weekly.
Neurologic examination (including vibrametry) and audiometry
were performed prior to start and 2 weeks and 3 and 6 months
after the end of cisplatin treatment.
Pharmacokinetic and pharmacodynamic calculations
The AUC of cisplatin was determined using the noncompartmental
trapezoidal method. Cisplatin was measured in plasma as platinum
by AAS according to a validated method (Ma et al, 1996). The
elimination rate constant k (h-1) was determined using the time
points at 4, 5, 6 h after start of the infusion. Curves were
extrapolated to infinity by using C(t)/k, where C(t) is the plasma
concentration at the latest time point ‘t’ (mostly 6 h after start of
infusion). The terminal half-life was calculated by ln 2/k (h). The
total plasma clearance (CL) of unbound platinum was calculated
by Dose/AUC (ml min1).
The area under the DNA-adduct – time (AUA) was determined
up to the last measured time point at 21 h after start of the infusion
(i.e. by using the time points 0, 4 and 21 h) by applying the
trapezoidal method. The parameter AUA has previously been
defined (Schellens et al, 1996).
Urinary platinum excretion was used to calculate the renal
clearance of unbound platinum during the first 24 h after start of
treatment.
TOXICITY AND RETREATMENT
At any subsequent cycle leukocyte counts had to beX2.0 109 l1
and plateletsX2.0 109 l1 100 109 l1. Patients were to be taken
off study in case of treatment delay because of drug-related toxicity
for more than 2 weeks, and any irreversible Xgrade 2
nonhaematologic toxicity (in particular neuro-, nephro- and
ototoxicity), excluding untreated nausea, vomiting and alopecia.
In case patients were taken off study, further treatment was left to
the discretion of the responsible physician.
End points of the study
The clinical and pharmacologic end points of the study were the
RR in stage IIIB and IV NSCLC and the toxicity of the treatment
and the feasibility of adaptive intrapatient dose adjustment to
achieve the desired exposure to cisplatin. The exposure to cisplatin
was defined by DNA adducts in WBC and AUC of unbound
platinum in plasma. Patients were considered evaluable for
response if they had received a minimum of three cycles of
cisplatin.
Course 1:
AUA<23 
and AUC<3.4
Course 2:
AUA<23
and AUC<3.4
Course 3:
AUC<3.4
then same dose all 
subsequent courses
Course 2/3:
AUC>3.4
All subsequent 
courses
Dose increase   max 30%
Dose increase
max 30%
Dose     decrease
A
Course 1:
AUA>23
and/or AUC>3.4
All courses:
same dose 
70 mg m_2
B
Figure 1 Algorithm for dose adaptation of cisplatin: (A) if the observed
AUA during course one is below the target of 23 (pg Pt h mg1 DNA) and
the AUC is below the safety limit of 3.4 (mg h ml1). (B) if the observed
AUA during course one is already higher than the target of 23 (pg Pt h mg1
DNA) and/or the AUC is higher than or equal to the safety limit of 3.4
(mg h ml1). (For further details see Methods section.)
Dose escalation of cisplatin
JHM Schellens et al
816
British Journal of Cancer (2003) 88(6), 814 – 821 & 2003 Cancer Research UK
C
lin
ic
a
l
Statistical analysis
No formal ‘a priori’ statistical design was chosen. The study was
performed in a relatively large patient population to enable
adequate assessment of the feasibility of intrapatient dose
escalation. The Pearson correlation coefficients were calculated
between dose and exposure parameters where appropriate. The
Spearman rank correlation coefficients were calculated between
exposure parameters and toxicity scores. Po0.05 was defined as
statistically significant.
RESULTS
In total, 76 patients were entered into the study between 1995 and
1999. Study evaluation was complete in 2001. The main
characteristics are given in Table 1. All patients were evaluable
for pharmacokinetics and toxicity. Four patients were not
evaluable for response, because they did not receive the minimum
number of three courses of cisplatin. Of these patients, two had
early disease progression and two refused further treatment
because of nausea and vomiting after the first and the second
course, respectively.
The 76 patients received in total 381 courses, which means that
on average five courses were administered per patient. The
achieved number of courses is 84% of the planned maximum of
six courses. In all, 18 patients did not complete the planned
cisplatin courses, for reasons outlined in Table 2. In 15 patients, a
treatment delay of 1 week was necessary and in 11 patients of 2
weeks, because of slow recovery of leukocytes and/or thrombo-
cytes. Of the 58 patients who received the planned six courses of
cisplatin, 39 patients reached a dose intensity of
60 mg m2 week1, 10 patients with a 1 week delay reached a dose
intensity of 52.5 mg m2 week1 and 9 with 2 weeks delay a dose
intensity of 47 mg m2 week1. The median dose intensity of all
patients was 54 mg m2 week1.
Pharmacokinetic data, DNA-adduct levels and dose
adaptations
Of the 75 patients, who received more than one course, in total 37
patients (49%) received a dose increase, because the initial
pharmacokinetic parameters were below the defined target level
during course one. The magnitude of the dose increases vs the
percentage of patients is shown in Figure 2. In individual patients,
the dose increase varied from 10 to 55%. The mean dose increase
was 28% (Tables 2 and 3). Of the 37 patients who received a dose
increase after the first course, 28 patients reached the target value
of DNA adducts during the second course and in nine patients a
modest (10–15%) further dose increase was necessary. In four
patients, the AUA remained below the target of 23 pg (Pt h mg1
DNA); however, further dose increases were restricted by the high
level of the AUC. The AUA and AUC data are given in Table 4.
The main pharmacokinetic data of cisplatin during course one
are given in Table 5. Total plasma clearance of unbound platinum
was 5837152 ml min1 and renal clearance was 164736 ml min1.
The clearance data obtained during course two and three were of
the same order as those of course one.
The correlation coefficient (R) between AUC and AUA during
course one was 0.61 (Po0.01; N¼ 76), during course two 0.51
(N¼ 75; Po0.01) and during course three 0.68 N¼ 65; Po0.01)
(Figure 3). The correlation coefficient between dose and AUC
during course one was 0.21 (not significant NS; N¼ 76) and
between dose and AUA 0.17 (NS; N¼ 76).
Tumour response
In total, 72 patients were evaluable for response. None of the
patients developed a clinical complete remission (CR). Twenty-
nine or 40% of the patients developed a partial remission (PR), 28
(39%) remained stable during the treatment period with cisplatin
and 15 (21%) showed progressive disease during or at the end of
the planned treatment with cisplatin. The responses per tumour
Table 1 Patient characteristics
Total entered 76
Male 49
Female 27
Median age (range) 56 (33–72)
Median WHO performance score (range) 1 (0–2)
Stage III B 27
IIIB with pleural effusion 6
IIIB with T4 tumour 7
IIIB with N3 nodes 14
IV 49
Prior chemotherapy 0
Prior radiotherapy 11
Table 2 Reasons for patients not to complete the six planned cisplatin
courses (total entered 76)
No. of cisplatin
administrations No. of patients Reason off study
1 2 Patient refusal
2 2 Patient refusal, early PD
3 5 3*PD, ototoxicity, delay >2 weeks
4 3 3*delay >2 weeks
5 6 3*PD, 3*delay>2 weeks
Table 3 Cisplatin dose during courses one and two
Course 1 2
Cisplatin (mg) Mean 127 162
s.d. 15 29
Range 105–165 105–185
N 76 75
60
50
40
30
20
10
0
0 51-6041-5031-4021-3011-20
Cisplatin dose escalation (%)
Fr
eq
ue
nc
y 
(%
)
1-10
Figure 2 Magnitude of the dose increase of cisplatin expressed as
percentage of the starting dose vs the percentage of patient (N¼ 76).
Dose escalation of cisplatin
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stage are given in Table 6. The median response duration in stage
IIIB was 34 weeks (range 20–54 weeks) and in stage IV 26 weeks
(range 14–38 weeks). All patients who developed a PR continued
with oral VP16 as single agent. Most patients needed an interval of
2–3 weeks instead of the planned 1 week to recover from grade
1–2 myelosuppression after the end of cisplatin treatment. The
median number of courses of VP16 was 3 (range 1–7).
Toxicity
The main toxicities observed are given in Table 7, scored as worst
toxicity per patient. The combination of dose intensive weekly
cisplatin plus daily low-dose VP16 induced significant myelosup-
pression with leuko- and granulocytopenia, which necessitated
dose delays of 1– 2 weeks in 18 patients. Two patients went off
study after three courses, four after four courses and three after
five courses, because recovery of granulocytes took more than 2
weeks. Mild to moderate anaemia was the most frequent
observation and the majority of patients (41 out of 76) needed
one or more red blood cell transfusions during treatment. Anaemia
developed gradually mostly after three courses. Mild to moderate
ototoxicity was observed; however, it did not lead to manifest
hearing loss. Most of the reported toxicities started to develop after
two to three courses
Also, mild to moderate nausea (grade 1– 2) and vomiting (grade
1–2) occurred frequently. Reversible grade 1 nephrotoxicity
developed in 14% of the patients and was therefore a relatively
infrequent toxicity. Neurotoxicity consisted of mild to moderate
paraesthesias, and sensory neuropathy, a common pattern
associated with intensive cisplatin therapy, which developed in
the majority of patients (72%).
No significant relations were found between exposure para-
meters (dose, AUC, AUA) and toxicity scores, including neuro-
toxicity parameters.
DISCUSSION
Assessment of the optimal treatment of advanced NSCLC has been
subject of numerous clinical trials. Cisplatin single-agent therapy is
clearly inferior to combination therapy with active agents,
including VP16, paclitaxel and gemcitabine. The combination
with VP16 has been extensively investigated and the RR in
advanced disease averages 30% (Klastersky, 1986). Prospective
trials aimed to improve the RR, time to progression (TTP) and
Table 4 Area under the DNA-adduct– time curve (AUA) in WBC and AUC of unbound platinum in plasma in 76 patients
Course 1 2 3 4 5 6
AUA (pg Pt h mg1 DNA) Mean 16.5 22.6 24.9 23.9 26.9 28.9
s.d. 3.2 4.1 4.6 4.4 5.3 4.8
Range 10.2–29.0 16.7–39.1 19.5–45.8 16.1–42.1 17.4–42.1 20.6–52.4
N 76 75 65 49 49 31
AUC (mg h ml1) Mean 2.1 2.9 2.7 ND ND ND
s.d. 0.5 0.6 0.4
Range 1.1–3.5 2.2–4.1 2.1–4.4
N 76 75 65
ND=not determined.
Table 5 Total plasma clearance (CL) of unbound platinum (Pt), urinary excretion (0–24 h after start of infusion), renal clearance, and
terminal half-life (t1/2) of Pt in plasma during course one
CL unbound Pt (ml min1) Urinary Pt excretion (% dose) Renal CL Pt (ml min1) t1/2 (h)
Mean 583 29 163 0.47
s.d. 152 6 36 0.16
Range 381–1223 11–38 87–262 0.31–1.06
N 76 69 69 76
0
20
40
60
0 1 2 3 4 5
AUC unbound Pt (g h ml_1)
AU
A 
(pg
 P
t.h
 g
_
1  
D
N
A)
course 1 (R=0.61)
course 2 (R=0.51)
course 3 (R=0.68)
Figure 3 Correlation between the exposure (AUC) to unbound
cisplatin during the first three courses and the DNA-adduct levels in
WBC (AUA). The correlation coefficients are given (R).
Table 6 Tumour response in 72 evaluable patients with advanced stage
IIIB or IV NSCLC
Stage IIIB Stage IV All patients
No. of patients 25 47 72
CR F F F
PR 15 (60%) 13 (30%) 29 (40%)
s.d. 10 (40%) 18 (38%) 28 (39%)
PD F 15 (32%) 15 (21%)
Dose escalation of cisplatin
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survival have focused on dose intensification of cisplatin in
combination with VP16. Gralla et al (1981) reported that cisplatin
120 vs 60 mg m2 plus vindesine every 4 weeks resulted in an RR of
43%, equal in both arms, but the TTP was 12 vs 5.5 months and the
survival was more than double favouring the high-dose arm. In
another randomised study of Gandara et al (1989), cisplatin
50 mg m2 on days 1 and 8 vs 100 mg m2 on days 1 and 8 in a
4-weekly schedule in stage IV NSCLC resulted in a low RR of 12%
in the low dose and 14% in the high-dose arm. In combination
with mitomycin C, which was the third arm of the study, the RR
was 27%. The highest dose intensity of cisplatin reached was
41 mg m2 week1.
Inspite of these high doses per course the RRs of high-dose
cisplatin are disappointing. Randomised studies have thus far not
shown survival benefit of regimens applying high doses of cisplatin
vs standard cisplatin containing treatment schedules in NSCLC
(Gandara et al, 1989; Font et al, 1999). In these studies, all patients
received either a high or a standard dose of cisplatin. The interval
between the administrations of cisplatin was usually 2–3 weeks.
Another important approach to intensify therapy with cisplatin is
to decrease the treatment interval, thereby increasing the dose
intensity. Studies by Planting et al have clearly shown that weekly
dose-intensive cisplatin at a dose of 70 mg m2 plus low daily
dose of 50 mg VP16 is feasible and active (Planting et al, 1993,
1994, 1995a, b, 1996a, b, 1997, 1999). Based on preclinical and
clinical data supporting the combination of cisplatin and VP16,
VP16 was added in an attempt to improve the activity of cisplatin
therapy (Tsai et al, 1989, Donnadieau et al, 1991; Wampler et al,
1992; Kanzawa et al, 1997). In NSCLC, weekly 70 mg m2 (weeks 1,
2, 3 and 5, 6, 7) of cisplatin plus low dose of VP16 was investigated
in stage IIIA, IIIB and IV patients (Planting, 1996). In the 17
patients with stage IIIB, of whom 13 completed therapy, the overall
RR was 35% (six out of 17 patients). In stage IV disease in that
study the overall RR in 29 patients was 31%. The same weekly
schedule of cisplatin plus VP16 induced favourable RRs in chemo-
naive pleural mesothelioma (Planting et al, 1994; 1995b), meta-
static melanoma (Planting et al, 1996b) and advanced cervical
cancer (in preparation), tumour types that are known to be only
marginally sensitive for chemotherapy.
In a retrospective pharmacologic study, we have shown that the
levels of DNA adducts formed in WBC as well as the AUC of
unbound platinum in plasma were highly correlated with the
likelihood of tumour response in 29 patients with advanced solid
tumours, mostly NSCLC, pleural mesothelioma, cervical cancer
and carcinoma of unknown primary site who were treated with
weekly cisplatin plus daily low-dose VP16 (Schellens et al, 1996).
Such positive relation was also established in a cohort of 16
patients with advanced H/N cancer treated with cisplatin as the
single agent. This has been the starting point for adaptive
intrapatient dose escalation with the aim to improve the RR of
cisplatin therapy. Two recent explorative studies in cervix cancer
(weekly cisplatin plus low-dose VP16) and H/N cancer (weekly
cisplatin as single agent) (submitted) revealed that the procedure
of dose adaptations using DNA-adduct levels and/or AUC of
cisplatin is feasible in a research setting, even when the turnaround
time for reporting of analytical and pharmacokinetic results is as
short as 1 week.
In the current phase II and pharmacologic study, the RR of the
weekly therapy of cisplatin plus low-dose VP16 was the primary
end point, besides assessment of the feasibility in a large
prospective study. The RR in stage IIIB was 60% in 25 patients
evaluable for response and 30% in 47 patients with stage IV
disease. The RR of 60% in 25 patients with stage IIIB is
encouraging compared with historical controls applying cisplatin
in combination with VP16 at a 3- or 4-weekly schedule and also
compared with the outlined weekly schedule of cisplatin plus low
dose of VP16 (Planting, 1996). Clearly, prospective randomised
studies are necessary to reveal whether the activity, and more
important the TTP and survival, can be increased by intrapatient
dose escalation of cisplatin. In stage IV disease, the RR of our
study was in the same range as reported by Donnadieu et al (1991)
and Planting (1996). However, the RR in the current study appears
to be higher than compared with cisplatin at a high dose as single
agent at a 3- or 4-weekly schedule (Gandara et al, 1989). Therefore,
development of other novel approaches is necessary to improve
the treatment outcome in patients with stage IV disease.
The 76 patients received on average 5.0, or 84%, of the planned
maximum of six courses. This illustrates that despite the dose
increase, the dose intensive schedule is practically feasible in
chemo-naive patients in good clinical condition. The achieved
median dose intensity of cisplatin of 54 mg m2 week1 is relatively
high considering the combination with daily VP16. The median
dose intensity of cisplatin in our study is comparable to the dose
intensity of weekly cisplatin in combination with radiation in
cervix cancer.
Prior to the execution of the study a dosing algorithm was
designed allowing maximally 30% dose escalations, which was
arbitrarily chosen for safety reasons. In most patients one dose
escalation was sufficient. In 49% of the patients, a dose increase of
10–55% was necessary to reach the defined target levels of DNA
adducts and/or AUC. The wide range of dose escalations reflects
the variability in the pharmacokinetics of cisplatin. In 24% (nine
out of 37 patients) of the patients who needed a dose increase, a
second increase was necessary after the second course, because the
target levels had not been reached after the first dose increase. In
five patients, the AUC level became higher than the upper limit of
Table 7 Main CTC graded toxicities in 76 patients that are probably or definitely related to cisplatin therapy. Toxicities are scored as worst grade per
patient
Toxicity Grade 1 N (%) Grade 2 N (%) Grade 3 N (%) Grade 4 N (%)
Leucocytopenia 18 (24%) 24 (32%) 13 (17%) 3 (4%)
Neutropenia 15 (20%) 29 (38%) 16 (21%) 6 (8%)
Thrombocytopenia 21 (28%) 23 (30%) 11 (14%) 2 (3%)
Anaemia 26 (34%) 42 (55%) 0 0
Neurotoxicity 55 (72%) 8 (10%) 0 0
Ototoxicity 29 (38%) 14 (18%) 0 0
Nephrotoxicity 11 (14%) 0 0 0
Alopecia 27 (36%) 16 (21%) F F
Nausea 48 (63%) 10 (13%) 4 (6%) F
Vomiting 27 (36%) 2 (3%) 2 (3%) 0
Diarrhoea 9 (12%) 1 (1%) 0 0
Anorexia 38 (50%) 7 (9%) 0 0
Fatigue 37 (49%) 9 (12%) 0 0
Dose escalation of cisplatin
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3.4 during course three, the level which was chosen for safety
reasons, although from course two to three no dose escalation was
applied. Apparently, this was caused by intrapatient variability in
pharmacokinetics of cisplatin. The maximum AUC reached was 4.4
in one patient.
In all patients during course one, the DNA-adduct levels could
be determined and dose escalations were based on adduct levels.
Theoretically, this parameter may be more of interest than
the AUC, because the DNA-adduct formation is considered to be
the cytotoxic lesion of cisplatin (Eastman and Schulte, 1988).
If the current strategy of intrapatient dose escalation is going to be
applied at a wider scale in the future, then the study design should
be simplified. The AUA was significantly correlated with the AUC
of cisplatin (Schellens et al, 1996). This is confirmed in the current
study, as demonstrated by the significant correlation between
DNA-adduct levels in WBC and the AUC during all investigated
three courses. The AUC may be used as the main parameter for
dose adaptation. In addition, the number of samples for estimation
of the AUC of cisplatin may be reduced. At present, the data of this
and other studies are being used to design a limited sampling
model in order to further improve the practical application of
adaptive dosing for cisplatin.
The main pharmacokinetic parameters of cisplatin, in particular
plasma clearance, terminal half-life and renal clearance, are in the
same range as previously described (Reece et al, 1987, 1989;
Schellens et al, 1996).
The toxicities of the applied dose-intensive cisplatin therapy
plus low-dose VP16 are mainly related to neurotoxicity, ototoxi-
city, haematologic and GI toxicity. The great majority (80%) of
patients developed mild (72%) to moderate (8%) neurotoxicity
that presented as paresthesias. Ototoxicity was another frequently
observed toxicity and 14% of the patients developed relevant but
reversible CTC grade 2 toxicity. It is anticipated that in particular
this toxicity precludes further dose intensification of cisplatin. This
toxicity was also observed in previous high-dose studies (Gandara
et al, 1989; Planting et al, 1995; Planting, 1996). The majority of the
patients also developed anaemia, which frequently necessitated
blood transfusions. This was also found in previous studies with
the weekly schedule of cisplatin plus low-dose VP16 (Planting et al,
1995b). On average, the GI toxicity was manageable. Only two
patients discontinued therapy because of subjective unacceptable
toxicity (scored as CTC grade 2 nausea and vomiting). Renal
toxicity was an unusual finding. Only 14% of the patients
developed grade 1 toxicity. This may be because of administration
of cisplatin in hypertonic (3%) NaCl, rigorous pre- and
posthydration and frequent instruction of the patient. We found
no significant relation between the dose intensity of cisplatin and
the observed toxicities. We anticipate that the main reason for this
lack of relation is the narrow range of the exposures to unbound
cisplatin during repeated courses. The coefficient of variation in
the AUC of unbound Pt was only 15% during course three. The
range of the AUC of unbound Pt was three-fold during course one,
which reduced to two-fold during courses two and three. Also, the
AUA data showed little variation most likely as a results of dose
adaptation
In conclusion, the strategy of intrapatient dose adjustment for
cisplatin is practically feasible in a research setting even when a
short turnaround time of 1 week is the limit for reporting of
results. At the applied initial dose level of 70 mg m2 in total 37
(49%) of the patients needed a dose increase, varying from 10 to
55% to reach predefined exposure levels.
The RR of 60% in stage IIIB NSCLC is encouraging. A
randomised study comparing individualised dose vs standard dose
cisplatin applying the same schedule of administration may
unravel whether the adaptive dosing strategy results in improved
TTP and survival. The latter end point should be considered the
primary objective in such pivotal trial. Prior to the execution of
such randomised study, we currently explore schedule-intensive
cisplatin in combination with gemcitabine as a basis for adaptive
dosing in NSCLC. In addition, combined modality of cisplatin-
based chemotherapy and radiation can be considered for stage IIIB
NSCLC. In stage IV disease, other novel concepts are needed to
improve therapy.
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